The Heinrich Wieland Prize has been jointly awarded to Professor Raphael Mechoulam, Hebrew University, Jerusalem and Professor Roger Nicoll the University of California, San Francisco for their research into cannabis and endocannobinoids. Professor Nepomuk Zoellner, chairman of the Board of Trustees of the Heinrich Wieland Prize, presented the prize at the Ludwig-Maximilians-University in Munich today. The scientists jointly received € 25,000 for their research.
The Heinrich Wieland Prize meanwhile looking back to a forty year history is an annual award for innovative research in the fields of biochemistry, chemistry and physiology of lipids and related substances. It is sponsored by Boehringer Ingelheim.
This year's winners established the role of lipids as neurotransmitters. These findings are noteworthy because they give further insight into the communication between neurons in the brain, an insight that may aid the development of new therapies in the fields of appetite regulation, inflammation and neuroprotection.
"Promoting innovation is one of our company's key principles," said Dr Andreas Barner, Member of the Board of Managing Directors and Head of Research, Development and Medicine at Boehringer Ingelheim. "As Boehringer Ingelheim aims to research better therapy options and to offer innovative medications to patients, we are delighted to foster innovative thinking and pioneering research that may lead to new therapies with an award like this."
"Presenting this award to the research community emphasizes our great interest and support for research in new basic physiological mechanisms which might provide a starting point for finding novel medicines" added Professor Dieter Hinzen, Head of Boehringer Ingelheim's largest R&D Center in Biberach, Germany.
"Our research proves that the brain synthesizes small, lipid constituents, also called endocanabinoids, binding to cannabinoid receptors and thus transmits signals between neurons in the brain," said Professor Mechoulam. Professor Nicoll added: "The endocannabinoids mediate a most unusual form of signalling in the brain as the neurons use the endocannabinoids to control their own activitation." - "We are very pleased that our scientific discoveries have been recognized with the Heinrich Wieland Prize and hope that further research will reveal how cannabonoids may be used on a cellular and a network level," stated Prof. Mechoulam and Prof. Nicoll.
Heinrich Wieland Prize
The Heinrich Wieland Prize is named after the German Nobel prizewinner Prof. Heinrich Otto Wieland. Since 1964, the Heinrich Wieland Prize has been awarded annually to promote research in lipids and related substances in chemistry, biochemistry, physiology and clinical medicine. This prize is among the leading international awards. It can look back to a 40 year long successful history in this year and has to date been presented to 56 scientists. Since 2001, Boehringer Ingelheim has sponsored the award.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2003, Boehringer Ingelheim posted net sales of 7.4 billion euro while spending more than one fifth of net sales in its largest business segment Prescription Medicines on research and development.
Contact:
Boehringer Ingelheim GmbH
Corporate Division Communications
Kerstin Felix
55216 Ingelheim am Rhein
GERMANY
Phone: +49/6132/77 90 40 0
Fax: +49/6132/77 66 01
webmaster@ing.boehringer-ingelheim.com